The Sunnybrook Dementia Study
Launched by SUNNYBROOK HEALTH SCIENCES CENTRE · Feb 25, 2013
Trial Information
Current as of October 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Sunnybrook Dementia Study is researching ways to better understand and treat different types of dementia, including Alzheimer's disease. The study uses advanced brain imaging techniques to look at changes in the brain over time, along with genetic tests and cognitive assessments. This will help doctors see how dementia progresses and how new treatments might work. So far, over 1,500 patients with various forms of dementia and 140 healthy elderly individuals have joined the study, contributing to valuable insights.
To participate, individuals need to be between 40 and 90 years old, fluent in English, and have completed at least 8 years of education. They should also have some cognitive ability, as measured by a simple test. Participants can expect to undergo annual assessments that involve brain scans and cognitive tests. The study aims to improve dementia diagnosis and treatment, making it a significant step towards better care for those affected by these conditions.
Gender
ALL
Eligibility criteria
- Patient Inclusion Criteria (General):
- • Age between 40 and 90 (inclusive)
- • Fluent in English
- • Completed 8 years of education or higher
- • Visual and auditory acuity adequate for neuropsychological testing
- • Mini-Mental State Exam (MMSE) score ≥ 16
- Patient Exclusion Criteria (General):
- • Possible secondary causes of dementia, concomitant or history of neurological or psychiatric illness (other than stroke or Parkinsonism)
- • History of alcohol or substance abuse or dependence within the past 2 years
- Normal Control Inclusion Criteria:
- • Age between 40-90
- • Fluent in English
- • Completed 8 years of education or higher
- • No significant memory complaints
- Normal Control Exclusion Criteria:
- • Being treated or history of being treated for psychiatric or neurological illness
- • History of alcohol or substance abuse or dependence within the past 2 years
- • Current use of psychoactive medications (e.g. antidepressant, neuroleptics, chronic anxiolytics or sedative hypnotics, etc.)
- • Medical contraindications to MRI
About Sunnybrook Health Sciences Centre
Sunnybrook Health Sciences Centre is a leading academic health science organization located in Toronto, Canada, renowned for its commitment to advancing patient care through innovative research and education. As a prominent clinical trial sponsor, Sunnybrook integrates cutting-edge medical research with clinical practice, focusing on a wide range of health disciplines, including cancer care, trauma, and cardiovascular health. The center collaborates with various stakeholders, including academic institutions, healthcare providers, and industry partners, to facilitate the development of novel therapies and improve health outcomes. With a robust infrastructure and a dedicated team of researchers and clinicians, Sunnybrook plays a pivotal role in translating scientific advancements into tangible benefits for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toronto, Ontario, Canada
Patients applied
Trial Officials
Sandra E Black, MD
Principal Investigator
Sunnybrook Health Sciences Centre
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials